Stanford Medicine is building a new data platform for our academic research community to do better clinical data science. Hospitals have a large amount of patient data and researchers have demonstrated the ability to reuse that data and AI approaches to derive novel insights, support patient care, and improve care quality. However, the traditional data warehouse and Honest Broker approaches that are in current use, are not scalable. We are establishing a new secure Big Data platform that aims to reduce time to access and analyze data. In this platform, data is anonymized to preserve patient data privacy and made available preparatory to Institutional Review Board (IRB) submission. Furthermore, the data is standardized such that analysis done at Stanford can be replicated elsewhere using the same analytical code and clinical concepts. Finally, the analytics data warehouse integrates with a secure data science computational facility to support large scale data analytics. The ecosystem is designed to bring the modern data science community to highly sensitive clinical data in a secure and collaborative big data analytics environment with a goal to enable bigger, better and faster science.
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Background:
Healthcare is at a nexus where the data generated during the course of clinical care or research can be used to advance both the science and practice of medicine. With the widespread adoption of electronic health records (EHR), driven by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 [Gold2016], most academic centers now have more than ten years of EHR data available for reuse. [Lowe2009, Evans2012, Danciu2014, Kunjan2015, Turley2016, Foran2017]. In addition, hospitals have a fast growing amount of data from sources such as radiology, pathology, and bedside monitoring that are ripe for reuse to improve patient care and to advance scientific discovery [Shah2019, Rajkomar2019]. A sampling of research in recent years at Stanford [Banda2019, Banerjee2019, Dunnmon2019, Gombar2019, Hernandez-Boussard2016, Hernandez-Boussard2019, Jung2019, Parthipan2019, Rajpurkar2018, Ross2019, Tamang2015, Tamang2017a, Tamang2017b, Wang2018] suggests that researchers are able to reuse the collected STRIDE has an associated cohort building tool, Anonymous Patient Cohort Discovery Tool [Lowe2009] , that returns patient counts matching a given query and is used to design studies prior to Institutional Review Board (IRB) submission. The tool is designed to answer the question "How many patients in the CDW contain these attributes?" No individual patient data is exposed during cohort search. A chart review tool, accessible after IRB approval [Grady2015], allows rapid view of the retrieved patient cohort. In addition, there is a real time Complex Event Processing (CEP) engine [Weber2010] , that uses HL7 feeds to identify potential research participants.
Stanford's Honest Broker [Choi2015], in part funded by Dean's Office and in part funded by the National Center for Advancing Translational Sciences (NCATS) Clinical and Translational Science Awards (CTSA), is composed of two teams. The Research IT team (RIT) at Technology & Digital Solutions has performed the role of data stewards since the release of STRIDE in 2008. RIT transfers data from our hospitals, normalizes the data for research use, develops Cohort and Chart review tools, develops de-identification pipelines and supports end users. The Research Informatics Center (RIC) in the Dean's Office represents the analytics team and was split up from RIT in 2017 and supports custom query development and extraction. The Honest Broker teams have provided over 5000 clinical data consults since 2008 resulting in hundreds of publications, including many that employ machine learning and other forms of AI techniques. The numbers have increased year over year. In 2019, approximately 650 studies involving 530 PIs and 1500 researchers were approved by IRB. Approximately 58% of the approved IRBs could use the existing STRIDE cohort and chart review tools in a self-service manner. The Honest Broker teams served over 800 consultations including both pre and post-IRB support.
Vision:
There is an appetite for diverse data types at Stanford as illustrated by a sampling of publications, e.g. , radiology [Dunnmon2019, Patel2020], echocardiography [Dykes2019] , and bedside monitoring [Miller2018] . Our Hospitals are currently accruing research usable data at a petabyte scale. For example, the current rate of growth for radiology and echo data is estimated at 450 TB/yr, bedside monitoring is estimated at 100 TB/yr, digital pathology at 1000 terabytes/yr. Research IT is starting to bring these datasets in a new STAnford medicine Research data Repository (STARR, http://starr.stanford.edu ) with the intent of a) making these rich but often proprietary sources of data "analysis-ready", b) linking the data to Clarity for "completeness", and c) bringing in ancillary data sources (e.g. PowerPath for digital pathology) to make the data metadata "rich". Our intent is to support the necessary data warehouses, data models, identified or anonymized non-human subject data, and analytical tools based on the data in STARR.
We also envision a world where we can bring more scientists to data, do better team science while preserving patient privacy, fail fast and innovate faster, and bring innovations to patients in a timely fashion.
Motivation:
Our existing ecosystem of STRIDE CDW, Cohort and Chart review tools, and our Honest Broker services are unable to keep up with growing demand for greater volume and complexity of data. Researchers are waiting longer for IRB approval, privacy, and security reviews, and Honest Broker services. In this section, we motivate our new clinical data science platform by discussing the gap between our current capabilities and our vision.
Firstly, the current system does not allow researchers to do self-service exploratory data analysis. Researchers get access to patient data either by filing an IRB request for identified patient data (not exploratory) or via an Honest Broker consultation for anonymized data (not self service). With the growing demand for data, the demand for IRB and Honest Broker services are rising. Growing number of researchers are frustrated with delays in starting their projects due to the arduous IRB process [Silberman2011]. The current system is not designed to support the growing enthusiasm for AI driven research.
We can reduce researcher reliance on Honest Broker services by enabling self-service pre-IRB access to anonymized EHR data. The idea of using anonymized CDW for pre-IRB studies is not new [Liu2009] and exists at other academic centers like UCSF ( https://informationcommons.ucsf.edu/ ). We expect that pre-IRB access to anonymized data will enable research teams to start their studies earlier and publish sooner. For example, with anonymized data a team may realize the need for advanced statistics skillset to account for the inherent biases in EHR data [Verheji2018] much before their IRB request is approved. In some cases, researchers will realize that the underlying data doesn't serve the original study requirements and consequently, they will avoid the arduous IRB process and reduce their cost. Finally, many researchers will be able to complete their research studies with anonymized data and will reduce the number who eventually need access to identified data thus reducing the likelihood of privacy breaches. In summary, enabling pre-IRB access to anonymized EHR data in a self-service fashion will reduce several of our current research bottlenecks and result in faster and better research outcomes.
Secondly, researchers find it difficult to extend their studies on Stanford datasets to non-Stanford data sources. The difficulty arises because we use a data model, STRIDE, that is idiosyncratic and non-standard. To extend the studies to alternate data sources, researchers engage in the complex legal process of data sharing agreements and then spend enormous resources transforming the data from one format to another. We propose to standardize on Observational Health Data Sciences Furthermore, there is a strong focus in OHDSI community on data quality and broad support for the analytical toolkits (aka methods library) that together strive to deliver consistency in cohort definition, analysis design, and reporting of results. Perhaps the most appealing aspect is that OHDSI is an open source public-private partnership and welcomes community participation. There is a robust community of end users, developers and thought leaders who are actively engaged in various shared repositories, discussion forums, training and workshops. The collection of learning resources are vast ( https://github.com/OHDSI/ ) and includes FAQs, code snippets and video lectures. Finally, OMOP is adopted at other CTSA sites e.g. , Albert Einstein College of Medicine -Montefiore Health, Columbia University, Icahn School of Medicine at Mt. Sinai.
Thirdly, current research computing infrastructure is not suited to modern clinical data science. Security issues are significant when handling patient data. It has been shown that even anonymized patient data can be combined with other publicly available data to re-identify patients [Emam2011]. In the hands of a malicious attacker, re-identification can lead to potential harm for vulnerable groups. Clinical notes, even when anonymized, may contain incidental PHI. Researcher laptops, which are secured by Stanford IT, have insufficient storage and compute to support complex analyses on these datasets. Large scale shared computing environments at Stanford, such as Sherlock ( https://www.sherlock.stanford.edu/ ), have the required storage and compute, but are not designed for sensitive patient data. Further, requiring individual labs or researchers to set up servers and manage constantly evolving security issues is infeasible, there are a number of well-publicized significant OS and/or architectural vulnerabilities ( https://nvd.nist.gov/ ) in any year that require sophisticated IT expertise.
We built a shared data science platform that is both secure and can provide the necessary computational power where researchers can run common data science workflows (e.g. TensorFlow using GPGPUs). We believe that such a platform will speed up novel computationally intensive healthcare research such as advanced phenotyping [Deisseroth2018], radiology [Dunnmon2019, Patel2020], echocardiography [Dykes2019], and bedside monitoring [Miller2018] . It will also improve patient data security, and reduce institutional risks.
Methods:
In this section, we outline the methods used in meeting the three objectives, a) enabling self-service pre-IRB access to anonymized EHR data, b) standardizing the data, and c) supporting researchers on a secure data science platform. Details of these methods are available in the Supplementary section.
Stanford EHR has over a hundred million clinical notes and our goal is to support monthly data refresh. We therefore need a secure infrastructure to support scalable storage and data processing. We expand our HIPAA compliant data center that hosts STRIDE to incorporate a public cloud, Google Cloud Platform (GCP), and use a mix of on-premise private cloud and public cloud capabilities. The hybrid infrastructure meets Stanford's data governance requirements (Supplementary material, Section 1) and minimum security requirements (Supplementary material, Section 2). To support the growing number of researchers using the EHR data, we use cloud native high performance analytical data warehouse Google BigQuery platform (Supplemental material, Section 3) to host and query the data. We adopt open source cloud agnostic workflow runner (Supplementary Material Section 4) for processing data. We anonymize all data including clinical text using best-in-class de-identification methods (Supplementary material, Section 6).
We normalize the EHR data to OMOP CDM v 5.3.1 (Supplementary Material Section 5) in a new analytical warehouse, STARR-OMOP. The NOTE table in OMOP is used to store the anonymized clinical text. Additionally, we populate the NOTE_NLP table to improve cohort design [Edinger2017]. We use a method that has incorporated both negation detection and history detection to convert clinical terms to known medical concepts (Supplementary material, Section 7).
For a secure data science facility, we collaborate with Stanford's Research Computing (SRC) team, to build a STARR integrated secure data science platform, Nero (Supplementary material, Section 8). Nero is HIPAA compliant and supports Big Data analytics. Armed with modern containerization and container orchestration technologies, the SRC team provides a range of services including hardware procurement and maintenance, OS upgrades, cloud integration, security requirements to meet HIPAA compliance, tool integration and research computing support. Researchers simply need to request access to the secure platform, but otherwise, need not worry about hardware procurement, and system security. In addition to data science tools such as Jupyter notebook, Python, anaconda, TensorFlow, RStudio, SAS etc., the data science platform supports OHDSI analytical tools.
Researchers directly access the anonymized non-human-subject dataset, STARR-OMOP-deid, in the secure Nero platform (Supplementary material, Section 9). The identified STARR-OMOP is available to the Honest Broker team on Nero and the researcher can seek post-IRB OMOP data after IRB approval via the Honest Broker team. Finally, data science training [Dolezel2019] is an important aspect of making the data self service. As a result, with support from Stanford CTSA award, RIT has launched training (Supplementary material, Section 10) on the use of the new anonymized data warehouse.
Analytics:
In this section, we outline the analytics derived from our new OMOP database and usage for our new data science platform.
We present analytics from our OMOP conversion using NCATS CTSA Common Metrics (( https://ncats.nih.gov/ctsa/projects/common-metrics )) in Table S5 (Supplementary material, Section 5). We show that OMOP database has ~2.7 million patients, over 60% of the patients have a diagnosis (ICD 9/10), over 40% have medication information (RxNorm), ~75% have lab information (LOINC), and over 90% of patients have clinical notes. In figure S5 .1 and table S5.2 we show the enhancement in standardized concepts over raw Clarity data.
We present analysis of PHI rate observed in our clinical text processing. Approximately, 100 million clinical notes are processed. These contain 33 billion words, the median number of words per clinical note is ~100 ( Figure S5 , Supplementary material, Section 5). There are ~22 million notes with no PHI findings, and ~1.3M notes with more than 100 PHI findings. Of the ~33 billion words, 1.4 billion are determined as PHI findings i.e. , approximately 4% of the words are found to be PHI ( Figure S6 .4, Supplementary material, Section 6). We also present the distribution of different PHI types (e.g. name, MRN, date) found in the notes and success rate of methods in finding these PHI e.g., NLP vs patient look up ( Figure S6 .5, Supplementary material, Section 6).
We present the number and percent of medical concepts found via text processing in Table S7 (Supplementary material, Section 7). Nearly 2 billion concepts (122K unique concepts) are found in 33 billion words representing 14 different vocabularies.
Finally, we present the performance of Google BigQuery. In Table S3 (Supplementary material, Section 6), we compare Oracle vs BigQuery and show that BigQuery is 10-100x faster. In Table S9 .1, we present the aggregate statistical performance of running Achilles Heel, data characterization queries, on STARR-OMOP dataset. Out of a total of 725 queries available in Achilles, an impressive 660 queries took less than 17 seconds, and median execution time was 3 sec. The longest query took 20 min and processed 13 GB of data. We expect that the research community will similarly experience ultra fast performance when using the STARR-OMOP-deid for analysis.
In table S9.3, we present performance of ATLAS running on Google Cloud using Google BigQuery against postgreSQL using the commonly available Medicare Claims Synthetic Public Use datafiles (DE-SynPUF, https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/DE_Syn_PUF ). The OHDSI SqlRender package ( https://github.com/OHDSI/SqlRender ) and JDBC drivers require performance tuning to support a new database type, in this case, BigQuery. In nearly all cases, the performance of ATLAS is comparable or faster when using BigQuery.
The Nero platform was launched in the summer of 2018. Nero has on-boarded 400 researchers representing 60 Stanford Principal Investigators. These researchers are working on High Risk data of various types, i.e. , not limited to biomedical data. Over 200 TB of storage has already been provisioned and we see a strong growth in use of GPGPUs on-premise. The STARR-OMOP-deid dataset was launched in the fall of 2019. A small subset of our Nero research community, ~30, have completed the user training at the time of writing. The ATLAS ( https://ohdsi-atlas.stanford.edu/ ) was launched in early 2020.
We propose to present the research impact of the new solutions in a subsequent manuscript. We are also in the process of running network studies using the OMOP database and case studies demonstrating the clinical text processing and will present the results in subsequent manuscripts.
Future work:
We are bringing in other data types in STARR such as radiology, bedside monitoring and pathology. We propose to extend the methods proposed in meeting the three objectives, a) enabling self-service pre-IRB access to anonymized EHR data, b) standardizing the data, and c) supporting researchers on a secure data science platform, to these other data types.
For example, we can link the datasets first, and then de-identify using the same protocol such that the HIPAA identifiers are deterministic anonymized across all datasets to preserve the linking.
For standardization of other data types, OMOP CDM does not offer a complete solution yet. However, such data can be captured using other well defined standards. For example, radiology Picture Archiving and Communication System (PACS) data is currently in pilot in OMOP CDM ( https://github.com/OHDSI/Radiology-CDM ), but the underlying DICOM (Digital Imaging and Communications in Medicine, https://www.dicomstandard.org/ ) data type is a well defined standard for radiology. RIT is building a metadata dataset that contains all metadata from images in the PACS Vendor Neutral Archive. This dataset can be linked to the OMOP dataset via image accession IDs and allow researchers a) unprecedented search capability and, b) run AI models taking the confounding factors such as device models [Badgeley2019] into account. For example, researcher can query the number of studies where patients have neurodegeneration and the image has annotations stored in Grayscale Softcopy Presentation State Storage (GSPS) Service-Object Pair (SOP) class, to estimate the effort in building test sets for their AI model. We have an image de-identification pipeline that is built for petascale data processing and can support both metadata and pixel scrubbing. We propose to present the pipeline in a subsequent manuscript.
Research IT's data center that hosts STARR and related portfolio of data warehouses and tools and data science platform, Nero, are designed for petascale data processing and team science respectively. We expect to integrate with other cloud platforms like AWS and Azure in time. 
[Dunnmon2019

Supplementary Material
In the supplementary material, we present details of data governance, data security implementation, technological and scientific methodologies used to generate the anonymized and standardized database, the secure data science environment and user support.
Section 1: Data governance policies
In this section, we present the data governance requirements for access to patient data, both anonymized and identified, and our workflow to meet the requirements.
The raw data in STARR data lake is Protected Health Information and is governed by the standards for privacy of individually identifiable health information by U.S. Department of Health and Human Services [HHS2002]. Research access to identified data (e.g., the identified STARR-OMOP) requires the researcher to get IRB approval specific to their study.
The requirements for the security and privacy of health information established by the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and HITECH Act explicitly do not apply to the protected health information (PHI) that has been de-identified, provided that there is "no reasonable basis to believe that the information can be used to identify an individual". Such de-identified or limited data sets do not require IRB approval, only Privacy Board Review and an appropriate Data Use Agreement.
Figure S1: Data governance for the STARR-OMOP dataset
The workflow is illustrated in Figure S1 . Research IT de-identifies the patient data (Section 6), in STARR-OMOP, into an anonymized dataset STARR-OMOP-deid and undertakes the Privacy Board Review. For the STARR-OMOP-deid dataset to be classified as non human subject research, Research IT does not allow subsequent linking the de-identified person IDs in the anonymized dataset to patient MRNs.
Researchers as part of STARR-OMOP-deid data access, sign a DUA referred to as a Data Privacy Attestation that prohibits recipients of anonymized data from attempting to re-identify the data subjects, or from resharing the data without permission.
detection, centralized logging among other requirements. All systems are required to support two-factor authentication and Research IT additionally supports Stanford's two factor authentication. All systems with High Risk data are required to support audit capabilities.
For scalability, we expanded our on-premise data center to cloud. While minimum security requirements may be clear, their implementation is often complex. For the on-premise servers, OS vulnerability management is a constant effort. Cloud providers take on the burden of maintaining secure OS images. On cloud, the complexity often comes from our lack of control over cloud products. For example, cloud providers may introduce features that unwittingly encourage users to export or use data in a non-approved or non-compliant manner. We may not be able to disable those features in a meaningful manner, and attempting to train users not to use those features may be ineffective. Furthermore, the default permission models do not distinguish very effectively between project resource visibility (configuration, metadata, resources, billing, etc.) and High Risk data visibility. It is often hard and complicated to provide effective separation of duties. Finally, the Cloud services are evolving over time, and the various products are not necessarily compatible with each other at a given point in time.
For example, Healthcare APIs and Cloud SQL import/export don't work with VPC Service Controls at the time of writing.
Both STARR and Nero go through Stanford Data Risk Assessment (DRA) process ( https://uit.stanford.edu/security/dra ) overseen by ISO and UPO. The DRA process is required at Stanford for new High Risk infrastructure or significant changes to existing infrastructure. These platforms also go through external penetration testing from time to time and ISO is part of the team that selects the pentest service provider, reviews the testing protocol and the final report. Prior to the launch of ATLAS Cohort tool ( https://ohdsi-atlas.stanford.edu/ ), we completed an external penetration testing and addressed the vulnerabilities in collaboration with ATLAS development team. Once in Avro, the databases are then uploaded to cloud and imported in GCP BigQuery (BQ, https://cloud.google.com/bigquery/ ) as a dataset for subsequent processing (see Figure S3 ). BQ is a highly performant analytical data warehousing technology that supports ANSI-compliant SQL and a powerful Application Programming Interface (API). It is not a transactional database like postgreSQL. While Stanford has exceptional on-premise computing resources, we believe that BQ provides a better overall query performance experience with significantly less IT overhead. It is not a low latency workflow, but the database scales exceptionally well for Big Data. BQ has proven to be highly performant for large scale GWAS [Pan2017].
At Stanford, we benchmarked a set of five complex queries using our highly optimized Oracle database running on the state-of-the-art on-premise infrastructure, and the same data, as BigQuery dataset via Avro ( Figure S3 ). These queries were submitted by the Honest Broker team as representative as typical queries requiring complex joins. The results of the benchmarking are presented in Table S3 . We see that queries on BigQuery execute 10-100x faster than on Oracle. Section 4: Data processing
In this section, we present our strategy for reproducible cloud agnostic petascale data processing using open standards.
We leverage the significant investment in development and evaluation of workflow orchestration frameworks (aka workflow engines or pipeline frameworks) [Leipzig2017] in recent years. For our workflow framework ( Figure S4 ), we adopt Common Workflow Language (CWL, https://www.commonwl.org/ ) and Cromwell workflow execution engine ( https://github.com/broadinstitute/cromwell ). We evaluated a number of existing workflow orchestration frameworks by deploying and testing the software -Apache Airflow ( https://airflow.apache.org/ ), Cromwell, Toil [Vivian2017], and Arvados ( https://arvados.org/ ). Cromwell workflow executor engine was selected due to its broad range of platform support, its maturity on the GCP, and its ease of deployment.
To support downstream reproducible science [Munafò2017], and data management efficiency, we consider the following requirements to be critical for our data processing: • Ability to track provenance of all outputs and every intermediate step -track every dependent source data and intermediate transformation so consumer of output has full visibility and understanding of where it came from. In our design, the source data is immutable (snapshots, not live databases or streams). • Ability to control reproducibility of all outputs including, a) ability to archive all versions of inputs including option to support purging to manage cost vs. reproducibility tradeoff, b) ability to transform in a deterministic fashion, c) ability to retain all software or logic used for transformation steps so we can run it in the future. • Ability to efficiently re-run transformations when new versions (snapshots) of the source data become available i.e. , run transformations when things change, not on a schedule • Ability to add quality checks in each transformation step, so pipelines fail early rather than letting errors propagate Aside from selection of a workflow manager, these requirements also lead to design considerations. For example, is a monolithic step in the transformation pipeline better than loosely coupled steps? Loosely coupled steps are better for progress monitoring, workflow transparency, and enable intermediate stop and restart while tightly coupled steps offer better reproducibility and version compatibility. In another example, what should constitute the archival "raw" data? While the original database (e.g., Oracle) dump can be stored as the raw, it is a proprietary and large file. Alternatively, the highly compressed and standard avro can be the "raw" but is also less reliable due to potential bugs in Oracle technology stack or our data processing code used transformation steps. Figure S4 : Workflow framework supports cloud services and user written tools.
A STARR data pipeline corresponds to a top level CWL workflow. Configuration is the CWL definitions of workflows and their command line interfaces (Tools). Technology adapters are implemented through the use of containerization (Docker) to better support reproducibility and portability. These adapters are organized into two main categories: A. Tool adapters consisting of self contained containers that focus on a specific set of functionality, for example, text de-identification. Scaling of tools is explicitly managed by the workflow framework by instantiating multiple instances across a distributed computing resource along with managing the partitioning of work among instances. B. Service adapters to general purpose technologies that reside outside the containers in which the adapters live. Services are self scaling and not dependent on the workflow framework for scalability. For example, for BigQuery, our workflow framework provides a service adapter with similar capabilities to Google's BigQuery command line tool ( https://cloud.google.com/bigquery/docs/reference/bq-cli-reference ). However, instead of simply wrapping this command line tool, its capabilities are mimicked where appropriate by leveraging BigQuery Java Client APIs ( https://googleapis.dev/java/google-cloud-clients/latest/index.html?com/google/cl oud/bigquery/package-summary.html ) so that functionality can be more easily adapted and extended to work within the framework. Additions in functionality include, i) Data-quality-checks that enables the execution of a BigQuery measurement query and then the execution of a list of predefined rules to ensure the measurements obtained match a given set of criteria (for example no null values in a column), ii) View-dataset that enables the creation/update of a dataset that comprises of authorized views on another dataset (for example, maintain a statically named latest dataset of a series of snapshot datasets), and iii) Metadata that adds support for querying the tables in a dataset and individual table schemas in a way that interoperates with CWL's command line interface. For our first launch of OMOP dataset, we limit the source data to Epic Clarity. The transformation process from Clarity to the OMOP-CDM can be summarized in five processes: ETL specifications, ETL code, mappings, data quality and data release. To design our ETL we current use OMOP-CDM v 5.3.1.The OHDSI consortium OMOP CDM github repository ( https://github.com/OHDSI/CommonDataModel/releases/tag/v5.3.1 ) specifies a list of all the tables present in the 5.3.1 schema and the explanation for each one of the columns. The repository also contains a guide to populate each of the tables, THEMIS rules ( https://github.com/OHDSI/Themis ), which contain high level specifications for ETL. Those rules specify among other things a criteria for patient and clinical events inclusion and, what information is expected at each one of the fields. As OMOP is a patient-centric model, a patient is only brought in, iff, a patient has at least one qualified clinical event in Clarity. An event is considered a qualified event if it actually happened to the patient. A medication that was ordered but never administered to the patient will not be brought in into the CDM. There are also a large number of note records, ~51 million, that do not contain any text and are suspected to be EHR artifacts such as failed attempts to create a clinical note that get registered in the Epic database. These are excluded from OMOP ETL.
In Table S5 .1: NCATS CTSA Common Metrics output
One of the main efforts to transform EHR data, Clarity, to the OMOP-CDM is the mapping of all the clinical information into standardized codes in the OHDSI OMOP vocabulary. The OHDSI OMOP vocabulary is a compendium of multiple terminologies and ontologies similar to the UMLS metathesaurus [UMLS2009]. The OMOP 5.3.1 vocabulary is organized across 39 domains, 371 classes and 430 relationships containing more than 6 million codes from 91 -vocabularies. By working with standardized codes, the ambiguity around specific use of strings, values or codes is reduced. The mapping process implies the translation of raw information (e.g. a string such as "ml") or codes in controlled terminologies or vocabularies (e.g. ICD10 R49.1) to standard codes in the OHDSI vocabulary. Figure S5.1 We use the OHDSI Achilles Heel tool for data quality analysis. This tool precomputes ~170 data characterizations that are iteratively used to improve the CDM. The improvements trigger three different actions: record removal, bug fixing and mapping changes. In an example of record removal, we have cases where some clinical events occurring prior to birth date. This is essentially a data entry error where proper adjudication is not feasible, and as a consequence the only option is to remove the record from the CDM. Mapping changes occur in two scenarios. The first is when the source data does not contain the mappings and it is necessary to do custom mapping given the raw data (e.g. a string). The second is when a different table in the source Clarity data is needed -the two Hospitals have different workflows resulting in different tables being populated in Clarity. This data quality process integrates with all the transformation by possibly modifying the specs and the subsequent code. It is essentially an iterative process of continuous improvement. Figure S5 .2 shows the distribution of words in notes. There are `~100M notes containing 33 billion words. Median number of words in a note is ~100, and ~9% notes have >1000 words, and 0.04% of the notes have >5,000 words. We investigated the notes that contained >5,000 words and found a few different reasons for their uncommon length. In some cases, the long notes include information of laboratory tests, radiology reports, medications and checklists beyond the regular use of those elements in a note. Discharge summaries sometimes contain information that is already present in progress notes as a way to document the progression of the patient during the stay. In some imaging reports, we found detailed information about the anatomy observed, specifically for cases where multiple systems or organs are being evaluated. Lastly, one of the EHR migrations resulted in merging of notes for a subset of our patients. Figure S5 .2: Distribution of words in ~100 million clinical reports (notes). There are approximately 33 billion words in 100 million notes.
Section 6: De-identification methods
In this section, we present anonymization techniques used to produce the STARR-OMOP-deid dataset. The anonymized clinical text is stored in NOTE table of the OMOP CDM.
Research IT achieves de-identification of STARR-OMOP data in accordance with NIST guidelines [NISTIR 8053] to meet the HIPAA Privacy Rule [HHS2002]. In particular, we use the Safe Harbor approach. Our approach to de-identification is similar to those presented by Ferrández et al [Ferrández2013] in that, we a) maximize patient confidentiality by redacting as much PHI as possible and may accidentally redact non-PHI; and b) leave de-identified data in a usable state preserving as much clinical information as possible.
Prior assessments [Fernandez2013] of clinical text de-identification techniques show that it is difficult to find a single approach that performs well in all cases. Clinical narratives can be fragmented and lack formatting, making the use of pre-trained traditional newswire Name Entity Recognition (NER) approaches limiting. Rule based techniques (e.g. pattern matching) are not scalable approaches. Research IT has developed a de-identification approach, TiDE (Text DEidentification), that combines a mix of pattern matching techniques, machine learning-based NER and Hiding in Plain Sight [Carrell2013] . While each of the techniques is only effective part of the time, together they are highly effective most of the time. We focus TiDE pipeline ( Figure S6 .1) on preserving patient privacy i.e., sensitivity of finding PHI is more important than specificity. In the first step, we find the locations of HIPAA identifiers.
TiDE has three separate sub-modules that find the HIPAA identifiers, a) the NLP name entity recognition module uses CoreNLP [Manning2014]] and can find random combinations of street name, city name, state name and zip code, b) the regular expression (regex) pattern matching to known patient PHI and, c) for entities like MRNs, SSN (e.g. 123-45-6789), email (e.g. john@example.org), IP, URL, we use an enumerated pattern matching. All HIPAA findings are stored in BigQuery. We then use BigQuery User-Defined Function (UDF, https://cloud.google.com/bigquery/docs/reference/standard-sql/user-defined-functions ) to select and merge all findings across the different methods to generate final list of candidate PHI that are then de-identified. For names and places, which are two of the three most frequent PHI in clinical text data, we use a surrogate approach [Carrell2013] aka Hiding in Plain Sight (HIPS) illustrated in Table S6 . In column 1, we show original PHI (patient and children names, date of visits) and PII (doctor's name). In column 2, we show a typical Safe Harbor implementation, a) patient and doctor names are identified and redacted using pre-existing information in Clarity database, b) one of the dates is identified using RegEx and jittered, and b) two of the children names are identified using NLP approaches and redacted. In column 3, we show the impact of surrogate approach to names. Here, one of the names (Madison) and a procedure date (5/7), previously undetected, are hidden with the HIPS approach. At the time of writing, the name replacement is gender aware but not ethnicity aware. Addresses are replaced randomly. The development of surrogate database is illustrated in Figure S6 .2. We collate the following sources, a) Bay Area census with addresses (bayareacensus.ca.gov), b) Health resources and services administration database with US addresses (data.hrsa.gov), c) FDA website with addresses (data.gov), d) Social security database with baby names (ssa.gov), and e) Medicare services database with physician names (data.cms.gov).
Original
Recently, the HIPS team presented the parrot attack [Carrell2019] and for this attack to succeed, we will need to assume an attack scenario where a) the attacker will maliciously hack in our secure data center and download de-identified data, b) the attacker will attempt to tag all real and surrogate PHI in the data, c) attacker will have access to data used to train our models, and d) attacker will be able to train a model to match ours. We believe that our system does not support this attack scenario. Firstly, Research IT does not provide any training data and secondly, our pipeline uses a collection of different machine learning algorithms and Safe Harbor method i.e. , it is not a single model that can be reverse engineered.
We use a manual QC process illustrated in Supplementary Figure S6. 3. In the case of clinical notes, we start with top 200 different note types that occur most frequently, pick 1000 random notes from these and of these, we pick a 100 that have a high amount of PHI found or high number of words found. These hundred go through a manual review for false negatives i.e. , we look for PHI left behind. For flowsheet (observational measurements) data, we take 80,000 rows and take them through a word frequency count. We then manually review the lowest frequency 10,000 words for potential PHI. Figure S6 .3: A stratified random sampling method for manual QC.
We considered using the i2b2 2014 Deidentification & Heart Disease dataset [Stubbs2014] to evaluate the performance of our de-identification pipeline but we could not find a meaningful set of comparison metrics due to procedural differences between the two. Firstly, we heavily use a priori information for a given patient. This information is not available for the i2b2 dataset. Secondly, our interpretation of the HIPAA Safe Harbor method is similar to the one used in MIMIC III [Johnson2016] and is different from the i2b2 dataset. For example, in the i2b2 dataset, age is considered PHI. However, in our case and in MIMIC III, only ages >89 are considered PHI. Other categories with difference from i2b2 approach include profession and location . Profession only becomes an identifier when it is very unique (e.g. Apple CEO). Location for i2b2 dataset includes organization as PHI and not just addresses. As with profession an organization becomes an identifier only if it is very unique and can be easily linked with the patient. In our strategy we used CoreNLP to recognize generic locations and organizations, however, by no means is CoreNLP capable of removing mentions of obscure company names. Figure S6 .4: Shows distribution of PHI count in ~100 million notes. Figure S6 .4 shows the distribution of PHI count found in notes. There are ~22 million notes with no PHI findings, and ~1.3M notes with more than 100 PHI findings. There are ~33 billion words, of which 1.4 billion are determined as PHI findings i.e. , approximately 4% of the words are found to be PHI. Some of the notes with high volumes of PHI are due to the presence of repeated elements inside checklists produced by dropdown menus, laboratory results and vital signs. The most common repeated elements are dates and clinician's names. Figure S6 .5: Distribution of different PHI types found in ~100 million notes. In the bottom graph, we present the occurrence of PHI by type. In the top graph, we present the methods used in finding a specific type of PHI. Figure S6 .5 presents findings from our text anonymization pipeline. We observe that names, dates, and location are the most common PHI types. We also find that the "mixed bag" approach of finding PHI is useful. For example, for patient and physician names, ~60% are found using patient information lookup and an additional 40% are found using NLP. Dates, MRNs and phone numbers benefit from regex search.
Section 7: Processing clinical text to identify known medical concepts
In this section, we present our method used to process clinical text to identify known medical concepts and store these concepts in the NOTE_NLP table in the OMOP CDM.
Text processing tools transform the unstructured information inside the notes into structure information that can be queried and stored in structured tables. The amount and type of information extracted from clinical notes vary from tool to tool. Most of the tools focus their efforts in mapping mentions of diseases, signs, and symptoms into a controlled terminology such as ICD or SNOMED ( Figure S7 .1). Through this mapping two different mentions such as "fever" and "temp > 37.5C" are mapped to the same concept inside a terminology. In this case the ICD-10 code R50.9.
For populating concepts in the NOTE_NLP table, we use a pipeline developed by LePendu et al [LePendu2013] , that has incorporated both negation detection and history detection. These contextual cues are based on NegEx [Chapman2001] and ConText [Chapman2007] and enable us to discern whether a term should not be attributed the current patient (e.g., lack of valvular dysfunction, or sister has muscular dystrophy). The pipeline extracts term mentions i.e. , string unique identifiers (SUI) within the UMLS [RRF2009] vocabulary. The terms are disambiguated ( Figure S7 .2) and then mapped to concepts in the OHDSI vocabulary ( Figure S7 .3) using an ETL similar to the OHDSI tool Ananke ( https://github.com/jmbanda/Ananke ) which maps from CUI to concepts. There are two ways to disambiguate via pre-processing, a) Word sense disambiguation algorithms that attempt to select the most likely sense of a string given the context, and b) the dictionaries used in the mapping are pruned and filtered using rules that attempt to increase precision. STARR uses the latter approach, we exclude terms with less than four characters and those present in the list of ambiguous terms provided by UMLS in AMBIGSUI.RRF. , each concept can contain modifiers that affect their interpretation and use in research. A mention of "high blood pressure" does not ascertain that the patient is experiencing the symptom. Context is necessary for an adequate interpretation [Harkema2009]. If the sentence, " family history of high blood pressure", human intelligence can safely interpret that the patient is not the one that suffers from high blood pressure. To translate this into structured information we need to introduce concept modifiers. These modifiers allow us to enhance the interpretation of the mapped concepts.
We populate the term_modifiers field in the NOTE_NLP table using the following strings:
1. experiencer_other: The absence of this modifier implies that the clinical event associated with the concept is being experienced by the patient. In the two examples, a) "The patient has coronary artery disease" and, b) "Coronary artery disease in father ", the modifier is present only in example b. 2. history_of_past: If this modifier is present, the clinical event associated with the concept likely occurred in the past. In the three examples, a) "she has chest pain", b) "She had hyperlipidemia" and, c) " Will schedule screening mammogram at next visit "; the modifier is present only in example a. 3. polarity_negated: The absence of this modifier implies the concept is present for the patient. If this modifier is present, the concept is negated. In the two examples, a) "the patient does not have any neurologic deficits" and, b) " she is being dialyzed", the modifier is present only in example a. Table S7 shows the distribution of concepts from different vocabularies and domain found in clinical notes respectively. Column 2 shows total counts of the concepts found (sum = 1.9 billion) and column 3 shows the percentage of occurance. Column 4 shows total unique counts (sum = 122K) and column four shows the percentage of unique count occurance. Finally, Nero makes commonly used research tools available using two approaches, a) for publicly available tools, the Nero team containerize the application stack and take it through a rigorous process of vulnerability scanning (e.g. OHDSI analytical tools), and b) for software-as-a-service (SaaS), the team partners with the provider to integrate the service with the Nero platform (e.g. https://stanford.md.ai/ ) in compliance with Stanford ISO requirements. The system administration of Nero platform includes a fully managed security service and research computing support.
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Stanford researcher then completes the requisite Data Use Agreement, also referred to as Data Privacy Attestation, attesting to the fact that they are requesting access to a High Risk non-human subject exploratory dataset. The attestation goes through the researcher's responsibilities for the data handling. Once a researcher is on Nero, and DUA is completed, they get access to the STARR-OMOP-deid BigQuery dataset and are added to a user support slack channel.
Once on Nero, they can use an interactive terminal or use Jupyter Hub to launch a preferred kernel (e.g. R or Python) or use batch mode via SLURM job scheduler. They can access their workspaces on-premise or Cloud and their preferred applications, bring their own data to their workspace, run batch mode or real time analysis, request new applications or troubleshooting help from the system administration team, and share code with collaborators using Stanford gitlab.
In Section 3) . These queries are from the OHDSI Achilles tool ( https://github.com/OHDSI/Achilles/tree/master/inst/sql/sql_server ) and are used to characterize the data quality. Out of 725 total queries available in Achilles, 660 queries took less than 17 seconds, and median execution time was 3 sec. The longest query took 1207 seconds (20 min) and processed 13GB of data. 
Section 10: User training
In this section, we present the training material available to our community.
As part of data access, researchers also get access to technical specification documents, training datasets -a one percent STARR-OMOP-deid dataset (for testing SQL queries ) and a synthetic dataset Data Entrepreneurs' Synthetic Public Use File (DE-SynPUF, https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/DE_Syn_PUF.html ) in OMOP 5.3.1 format, and access to Stanford gitlab with Jupyter notebooks compatible code. The specifics of ETL code used to transform data from Clarity to OMOP is made available upon request.
Research IT offers hands-on training sessions that help researchers with understanding and use of OMOP CDM, STARR-OMOP-deid dataset, and the Nero research computing environment.
